HCV-Trials.com : A regularly updated website with all most recent clinical trials data in HCV infection

2D Phase IIa Study: paritaprevir /ritonavir + dasabuvir + ribavirin for genotype 1
Poordad F. NEJM 2014;368:45-53

AGATE-I Study: OBV/PTV/r + RBVin genotype 4 with cirrhosis
Asselah T. Lancet Gastroenterol Hepatol 2016;1:25-35 ; Asselah T. EASL 2016, Abs. SAT-278, J Hepatol 2016;64:S827

AGATE-II Study: OBV/PTV/r + RBV in genotype 4 Egyptian patients without or with cirrhosis
Waked I, Lancet Gastroenterol Hepatol 2016;1:36-44 ; Waked I, EASL 2016, Abs. SAT-166, J Hepatol 2016;64:S772

AI444040 Study: DCV + SOF ± RBV for genotypes 1, 2 and 3
Sulkowski MS. NEJM 2014;370:211-21

AL-335-604 study: AL-335 + ODV ± SMV in naïve patients, phase II
Gane E. AASLD 2016, Abs. PS-153

ALLY-1 Study: DCV + SOF + RBV for advanced liver disease and post-liver transplant recurrence
Poordad F. Hepatology 2016; 63: 1493-505

ALLY-2 Study: DCV + SOF for HCV in HIV co-infection
Wyles DL. N Engl J Med. 2015 Aug 20;373(8):714-25.

ALLY-3 Study: DCV + SOF for HCV genotype 3
Nelson DR. Hepatology 2015;61:1127-35

ALLY-3+ study: DCV + SOF + RBV for HCV genotype 3 with advanced fibrosis or cirrhosis
Leroy V. Hepatology 2016; 63: 1430-41

ASPIRE Study: SMV + PEG-IFN + RBV for genotype 1 experienced patients
Zeuzem S. Gastroenterology 2014;146:430-41

ASTRAL-1 study: SOF/VEL in genotype 1, 2, 4, 5 or 6
Feld JJ. N Engl J Med. 2015;373:2599-607; Younossi ZM, J. Hepatology 2016;65:33-9

ASTRAL-2 study: SOF/VEL vs SOF + RBV in genotype 2
Foster GR. N Engl J Med 2015; 373: 2608-17 & Sulkowki M. AASLD 2015; Abs. 205

ASTRAL-3 study: SOF/VEL vs SOF + RBV in genotype 3
Foster GR. N Engl J Med 2015; 373: 2608-17

ASTRAL-4 Study: SOF/VEL in patients with decompensated liver disease
Curry MP. N Engl J Med 2015; 373: 2618-28

ASTRAL-5 study: SOF/VEL in HIV coinfection
Wyles D, Clin Infect Dis 2017 ; 65 :6-12

ATOMIC Study: SOF + PEG-IFNα-2a + RBV for HCV genotypes 1, 4, 6
Kowdley KV. Lancet 2013;381:2100-7

ATTAIN Study: simeprevir versus telaprevir, with PEG-IFN + RBV in previous non responders with genotype 1
Reddy KR. Lancet Infect Dis. 2015;15:27-35

AVIATOR Study: paritepravir /ritonavir ± ombitasvir ± dasabuvir ± ribavirin in genotype 1
Kowdley KV. NEJM 2013; 370:222-32

BOSON Study: SOF + RBV ± PEG-IFN for genotypes 2 and 3
Foster GR. Gastroenterology. 2015 Nov;149(6):1462-70

C-212 Study: SMV + PEG-IFN + RBV for genotype 1 in HIV co-infection
Dieterich D. CID 2014;59:1579-87

C-BREEZE-2 Study: ruzasvir + uprifosbuvir for 12 weeks in genotype 1-6
Lawitz E. AASLD 2017, Abs. 61

C-CORAL Study: elbasvir/grazoprevir for genotype 1, 4, 6
Wei L. J Gastroenterol Hepatol. 2019; 34:12-21

C-CREST study, Part A: GZR + EBR or MK-8408 + MK-3682 for genotypes 1, 2 and 3 - Phase II
Gane EJ. Lancet Gastroenterol Hepatol 2017 ; 2 :805-813

C-CREST study, Part B: uprifosbuvir (MK-3682)/GZR/ruzasvir (MK-8408) fixed-dose combination ± RBV for genotypes 1, 2 and 3 - Phase II
Lawitz E. Lancet Gastroenterol Hepatol 2017 ; 2 :814-823

C-CREST study, Part C: 16 weeks of uprifosbuvir/GZR/RZR fixed-dose combination + RBV for genotypes 1, 2 and 3 after failure of 8 weeks of treatment
Wyles D. Hepatology 2017 ; 66 :1794-1804

C-EDGE co-infection study: grazoprevir / elbasvir in HIV coinfection
Rockstroh JK. Lancet HIV 2015;2:e319-e327

C-EDGE CO-STAR: grazoprevir/elbasvir for HCV infected drug users on opiod replacement therapy
Dore GJ. Ann Intern Med 2016;165:625-636, EASL 2016, Abs. SAT-163, J Hepatol 2016;64:S771 & AASLD 2016, Abs. 871

C-EDGE Experienced Study: grazoprevir/elbasvir ± RBV in previous failure to PEG-IFN + RBV
Kwo P. Gastroenterology 2017;152:164-175; EASL 2015, Abs. P0886

C-EDGE HEAD-TO-HEAD Study: GZR/EBR vs SOF + PEF-IFN + RBV in genotype 1 or 4 infection
Sperl J. J Hepatology 2016; 65:1112-1119

C-EDGE IBLD: elbasvir/grazoprevir for HCV infected patients with inherited blood disorders (IBLD)
Hezode C, Hepatology 2017 ; 66 :736-45

C-EDGE TN Study: grazoprevir / elbasvir in genotype 1, 4 or 6
Zeuzem S. Ann Intern Med 2015; 163:1-13

C-ISLE study: EBR/GZR + SOF ± RBV in genotype 3 and cirrhosis
Foster GR. Hepatology 2018;67:2113-26

COMMAND GT2/3 Study: daclatasvir + PEG-IFN + RBV for genotype 2 or 3
Dore GJ. Gastroenterology 2015;148:355-66

COMMAND-1 Study: daclatasvir + PEG-IFN + RBV for genotype 1 or 4
Hezode C. Gut 2015;64:948-56

COMMAND-3 Study: DCV vs TVR, in combination with PEG-IFN + RBV, for genotype 1a or 1b
Jacobson I. World J Gastroenterol 2016;22:3418-31

COMMIT Study: SMV + DCV in genotype 1b
Hezode C, Liver International 2017 ; 37:1304-13

CONCERTO-1 Study: SMV + PEG-IFNα-2a + RBV for genotype 1
Hayashi N. J Hepatol 2014;61:219-227

CONCERTO-2 Study: SMV + PEG-IFNα-2a + RBV for genotype 1
Izumi N, J Gastroenterol 2014;49:941-53

CONCERTO-3 Study: SMV + PEG-IFNα-2a + RBV for genotype 1
Izumi N, J Gastroenterol 2014;49:941-53

CONCERTO-4 Study: SMV + PEG-IFNα-2b + RBV for genotype 1
Kumada H. Hepatol Research 2015;45:501-13

CORAL-I Study: OBV/PTV/r + DSV + RBV in liver transplantation with recurrent genotype 1 infection
Kwo PY. NEJM 2014;371:2375-82

CORAL-I Study cohort 2: OBV/PTV/r + DSV ± RBV for post-transplant genotype 1 HCV recurrence
Mantry PS. AASLD 2015, Abs. 1084

CORAL-I study cohorts 3 to 6
Agarwal K, EASL 2017, Abs. FRI-267

COSMOS Study: SOF + SMV ± RBV for genotype 1 - Phase Iia
Lawitz E. Lancet 2014;384:1756-65

C-SALT Study: grazoprevir + elbasvir in genotype 1 with Child-Pugh B cirrhosis
Jacobson IM. EASL 2015, Abs. O008

C-SALVAGE Study: grazoprevir + elbasvir + RBV in genotype 1 with failure to PI-based regimen
Forns X. J Hepatology 2015; 63: 564-72

C-SCAPE Study: elbasvir ± grazoprevir ± RBV in genotypes 2, 4, 5 or 6
Brown A. J Viral Hepat 2017, Nov 20 (Epub)

C-SLAM study: LDV/SOF vs SOF + SMV in acute hepatitis C
Basu PP. AASLD 2015, Abs. 1074

C-SURFER Study: grazoprevir + elbasvir in genotype 1 with chronic kidney disease
Roth D. Lancet. 2015 Oct 17;386(10003):1537-45

C-SURGE: uprifosbuvir/grazoprevir/ruzasvir for genotype 1 with prior DAA-failure
Wyles D. Hepatology 2017 ; 66 :1794-1804

C-SWIFT Study: elbasvir/grazoprevir + SOF in genotypes 1 or 3, with or without cirrhosis
Lawitz E. Hepatology 2017;65:439-50

CURRY Study: SOF + RBV for HCV with liver cancer before transplantation
Curry MP. Gastroenterology 2015;148:100-107

C-WORTHY Study: grazoprevir + elbasvir ± ribavirin for genotype 1
Sulkowski M. Lancet 2015;385:1087-97

C-WORTHY Study part B: grazoprevir + elbasvir ± ribavirin, 12 weeks vs 18 weeks in genotype 1
Lawitz E. Lancet 2015;385:1075-86

C-WORTHY Study part C: grazoprevir + elbasvir ± RBV in genotype 1b
Vierling JM. EASL 2015, Abs . P0769

C-WORTHY Study part D: grazoprevir + elbasvir + RBV in genotype 3
Gane E. J Viral Hepat. 2017 ; 10 :895-9

Egyptian Ancestry Study: SOF + RBV for HCV genotype 4
Ruane P. J. Hepatology 2015;62:1040-6

ELECTRON Study: SOF-based therapy for genotypes 1, 2 and 3
Gane EJ. NEJM 2013;368:34-44

ENDURANCE-1 Study: glecaprevir/pibrentasvir in genotype 1 without cirrhoss
Zeuzem S. NEJM 2018; 378:354-69

ENDURANCE-2 Study: glecaprevir/pibrentasvir in genotype 2 without cirrhosis
Asselah T. Clin Gastroenterol Hepatol 2017 ; Sept 22 (Epub)

ENDURANCE-3 Study: glecaprevir/pibrentasvir vs SOF + DCV in genotype 3 without cirrhosis
Zeuzem S. NEJM 2018;378:354-69

ENDURANCE-4 Study: glecaprevir/pibrentasvir in genotype 4, 5 or 6
Asselah T. Clin Gastroenterol Hepatol 2017 ; Sept 22 (Epub)

ENDURANCE-5, 6 Study: glecaprevir/pibrentasvir in genotype 5 or 6
Asselah T. Lancet Gastroenterol Hepatol 2018; Nov 1 (Epub ahead of print)

EXPEDITION-I : glecaprevir, pibrentasvir, genotype1, genotype 2, genotype 4, naïve, IFN-experienced, SOF-experienced, cirrhosis
Forns X. Lancet Infect Dis 2017; 17:1062-8

EXPEDITION-2 Study: glecaprevir/pibrentasvir in patients with HIV co-infection
Rockstroh J. Clin Infect Dis 2018;67:1000-17

EXPEDITION-IV Study: glecaprevir/pibrentasvir in patients with renal impairment
Gane E. NEJM 2017 ; 377 :1448-55

EXPEDITION-8 Study: glecaprevir/pibrentasvir 8 weeks in patients with cirrhosis
Brown RS. AASLD 2018, Abs. LB-7

EXPEDITION-V Study: GLE/PIB in patients with renal impairment
Gane E. N Engl J Med. 2017;377:1448-55

FISSION Study: SOF + RBV vs PEG-IFNα-2a + RBV for HCV genotype 2 and 3
Lawitz E. NEJM 2013;368:1878-87

FUSION Study: SOF + RBV (12 vs 16 weeks) for HCV genotypes 2 and 3
Jacobson IM. NEJM 2013;368:1867-77

GALAXY study: SMV + SOF ± RBV in recurrent genotype 1 HCV infection post liver transplantation
O’Leary JG. Transplant International 2017; 30:196-208

GARNET Study: OBV/PTV/r + DSV 8 weeks in genotype 1b
Welzel TM. Lancet Gastroenterol Hepatol. 2017; 2:494-500

GEODE-II Study: OBV/PTV/r + DSV + low dose RBV in genotype 1a
Poordad F. AASLD 2016, Abs. 872

GIFT-I Study: ombitasvir/paritaprevir/ritonavir for genotype 1b japanese patients
Kumada H. Hepatology 2015; 62:1037-1046

Glecaprevir/Pibrentasvir in genotype 1 with failure to NS5A-inhibitor plus sofosbuvir
Sulkowski MS. AASLD 2018, Abs. 0226

GS-9451/GS-9256 Failure Study: SOF + PEG-IFN + RBV for genotype 1 and prior failure to DAA
Pol S. Hepatology 2015; 62:129-34

GS-US-367-1168 Study: SOF/VEL + GS-9857 in genotype 1 - Phase II
Lawitz E, Gastroenterology 2016; 151:893-901

GS-US-367-1169 Study: SOF/VEL + GS-9857 in genotype 2, 3, 4 or 6 - Phase II
Gane EJ, Gastroenterology 2016; 151:902-909

HCV Recurrence Post-Transplant Study: SOF+ RBV for recurrent HCV infection after liver transplantation
Charlton M. Gastroenterology 2015;148:108-17

HEPNET ACUTE HCV IV study: 6 weeks LDV/SOF for acute hepatitis C
Deterding K, Lancet Infect Dis 2017; 17:215-22

IMPACT Study: SMV + DCV + SOF in HCV genotype 1 with decompensated liver disease
Lawitz E. J Viral Hepat 2017; 24:287-94

ION-1 Study: LDV/SOF ± RBV for genotype 1
Afdhal N. NEJM 2014; 370:1889-98

ION-2 Study: LDV/SOF ± RBV for pre-treated genotype 1
Afdhal N. NEJM 2014;370:1483-93

ION-3 Study: LDV/SOF ± RBV for naïve genotype 1
Kowdley KV. NEJM 2014;370:1879-88

ION-4 Study: LDV/SOF in HIV co-infection
Naggie S. N Engl J Med. 2015 Aug 20;373(8):705-13

Japanese 2D Study: OBV/PTV/r in treatment-experienced Japanese patients
Chayama K. Hepatology 2015;61:1523-32

Japanese SOF + RBV Study: SOF + RBV in genotype 2
Omata M. J Viral Hepatitis 2015;21:762-8

LDV/SOF ± RBV in genotype 3 or 6 – Phase 2
Gane EJ, Gastroenterology 2015;149:1454-61

LDV/SOF Failure Study: LDV/SOF for retreatment of genotype 1 with prior failure to LDV/SOF
Lawitz E. EASL 2015, Abs. O005

LDV/SOF in kidney transplant recipients
Colombo M, Ann Intern Med 2017; 166:109-117

LDV/SOF for 12 weeks in patients with genotype 1 and severe renal impairment
Lawitz E. AASLD 2017, Abs. 1587

LDV-SOF Japanese Study: LDV/SOF ± RBV for genotype 1 in Japanese (GS-US-337-0113)
Mikozami M, Lancet Infect Dis 2015;15:645-53

LEAGUE-1 study: daclatasvir + SMV ± RBV for genotype 1
Zeuzem S, J Hepatol 2016; 64:292-300

LEPTON Study: SOF/VEL + GS-9857 genotype 1 or 3 Phase II
Gane EJ, Gastroenterology 2016; 151:448-456

LONESTAR Study: LDV/SOF ± RBV for genotype 1 - Phase II
Lawitz E. Lancet 2014;383:515-23

LONESTAR-2 Study: SOF + PEG-IFN + RBV for genotypes 2 and 3 in prior failure
Lawitz E. Hepatology 2015;61:769-75

M14-103 Study: ombitasvir/paritaprevir/ritonavir + dasabuvir + RBV for genotype 1 on opioid replacement therapy
Lalezari J. J Hepatology 2015;63:364-9

MAGELLAN-I Study, Part 1 : Glecaprevir+ Pibrentasvir in genotype 1 with failure to DAA regimen - Phase II
Poordad F. Hepatology. 2017 ; 66 : 389-97

MAGELLAN-I Study, Part 2 : Glecaprevir, pibrentasvir, genotype 1, genotype 4, NS3-experienced, NS5A-experienced, cirrhosis, no cirrhosis
Poordad F, Hepatology. 2018;671253-1260 & Pilot-Matias T, EASL 2017, Abs. SAT-204

MAGELLAN-2 Study: glecaprevir/pibrentasvir in liver or kidney transplanted patients
Reau N. Hepatology 2018;68:1298-1307

MAGELLAN-3 Study: GLE/PIB + SOF + RBV in patients who failed GLE/PIB
Wyles D. J Hepatol. 2019 Mar 8 (Epub ahead of print)

MALACHITE study: OBV/PTV/r + DSV ± RBV versus telaprevir + PEG-IFN + RBV in genotype 1
Dore G. J Hepatol 2016; 64:19-28

NEUTRINO Study: SOF + PEG-IFNα-2a + RBV
Lawitz E. NEJM 2013;368:1878-87

NIAID ERADICATE Study: LDV/SOF for genotype 1 in HIV co-infection
Osinusi A. JAMA 2015; 313:1232-9

NIAID FOUR-WEEK Study: LDV/SOF + vedroprevir or LDV/SOF + vedroprevir + GS-9669 in genotype
Kohli A. Ann Intern Med 2015;163:899-907

NIAID SYNERGY GT4 Study: LDV/SOF in genotype 4
Kohli A. Lancet Infect Dis. 2015 Sep;15(9):1049-54

NIH SPARE Study: SOF + RBV in genotype 1 with advanced liver disease
Oisinusi A . JAMA 2013;310:804-11

OPTIMIST-1 Study: SMV + SOF for genotype 1 and no cirrhosis
Kwo P. Hepatology. 2016 Aug; 64:370-80

OPTIMIST-2 Study: SMV + SOF for genotype 1 and cirrhosis
Lawitz E. Hepatology. 2016 Aug;64(2):360-9

OSIRIS Study: SMV + PEG-IFN + RBV in genotype 4
Asselah T. PLoS One 2017 Jan 5;12(1):e0168713

PEARL I Study: ombitasvir/paritaprevir/ritonavir ± ribavirin for HCV genotype 4
Hezode C. Lancet 2015; 385:2502-9

PEARL II Study: ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin for HCV genotype 1b
Andreone P. Gastroenterology 2014;147:359-65

PEARL-III and IV Studies: ombitasvir / paritaprevir /ritonavir + dasabuvir ± ribavirin for HCV genotype 1
Ferenci P. NEJM 2014;370:1983-92

PEARL-I Study – Part 2 : ombitasvir/paritaprevir/ritonavir ± ribavirin for HCV genotype 1b
Lawitz E. Gastroenterology 2015; 149: 971-80

PHOTON-1 Study: SOF + RBV in HCV-HIV co-infection
Sulkowski M. JAMA 2014;312:353-61

PHOTON-2 Study: SOF + RBV in HCV-HIV co-infection
Molina JM. Lancet 2015;385:1098-1106

PLUTO Study: SMV + SOF in genotype 4
Buti M, Aliment Pharmacol Ther 2017;45:468-75

POLARIS-1 study: SOF/VEL/VOX in NS5A inhibitor-experienced patients with genotype 1 to 6
Bourlière M. NEJM 2017; 376:2134-46

POLARIS-2 study: SOF/VEL/VOX 8 weeks vs SOF/VEL 12 weeks in patients with genotype 1 to 6
Jacobson IM. Gastroenterology 2017; 153:113-22

POLARIS-3 study: SOF/VEL/VOX 8 weeks vs SOF/VEL 12 weeks in patients with genotype 3 and cirrhosis
Jacobson IM. Gastroenterology 2017, 153:113-22 & Foster GR. AASLD 2016, Abs. 258

POLARIS-4 study: SOF/VEL/VOX vs SOF/VEL in genotypes 1 to 6 with non-NS5A inhibitor experience
Bourlière M. NEJM 2017; 376:2134-46

POSITRON Study: SOF + RBV for HCV genotypes 2 and 3
Jacobson IM. NEJM 2013; 368:1867-77

PROMISE Study: SMV + PEG-IFN + RBV for genotype 1 and relapse to prior IFN therapy
Forns X. Gastroenterology 2014;146:1669-79

PROTON Study: SOF + PEG- IFNα-2a + RBV for genotypes 1, 2 and 3
Lawitz E. Lancet Infect Dis 2013;13:401-8

QUARTZ II-III : OBV/PTV/r + SOF RBV in genotype 2 or 3
Shafran SD. J. Viral Hep 2018; 25:118-25.

QUARTZ-I Study: OBV/PTV/r + DSV + SOF ± RBV for HCV genotype 1 after failure of DAA regimens
Poordad F. AASLD 2015, Abs. LB20, EASL 2016, Abs. SAT-156, J Hepatol 2016; 64:S767

QUEST-1 Study: SMV + PEG-IFN + RBV for genotype 1
Jacobson IM. Lancet 2014;384:403-13

QUEST-2 Study: SMV + PEG-IFN + RBV for genotype 1
Manns M . Lancet 2014;384:414-26

RESOLVE study: SOF/VEL/VOX 12 weeks in treatment experienced patients
Covert E. AASLD 2018, Abs. 0583

RESTORE Study: SMV + PEG-IFNα-2a + RBV for HCV genotype 4
Moreno C. J Hepatol 2015;62:1047-55

Retreatment study: SOF/VEL + RBV in prior NS5A failure-Phase II.
Gane EJ, Hepatology. 2017 ; 66 :1083-9

REVENGE: retreatment with SOF + EBR + GZR + RBV after failure with SOF + (LDV or DCV or SMV)
De Ledinghen V. Clin Infect Dis 2017, Oct 25 (Epub)

RUBY-I Study: ombitasvir/paritaprevir/ritonavir + dasabuvir ± RBV for HCV genotype 1 with renal impairment
Pockros PJ. Gastroenterology 2016 ; 150:1590-8

RUBY-I Study, cohort 2: ombitasvir/paritaprevir/ritonavir + dasabuvir ± RBV for HCV genotype 1 with renal impairment
Vierling JM. AASLD 2016, Abs. 886

RUBY-II Study: ombitasvir/paritaprevir/ritonavir ± dasabuvir for HCV genotype 1a or 4 with severe renal impairment
Gane E. AASLD 2016, Abs. 935

SAPPHIRE-I Study: ombitasvir/paritaprevir/ritonavir + dasabuvir + ribavirin for genotype 1
Feld JJ. NEJM 2014;370:1594-1603

SAPPHIRE-II Study: ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin for genotype 1 with failure to PEG-IFN + RBV
Zeuzem S. NEJM 2014;370:1604-14

SIRIUS Study: LDV/SOF ± RBV for genotype 1 and cirrhosis with non response to prior PI therapy
Bourlière M. Lancet Infect Dis 2015;15:397-404

SOF Failure Study: LDV/SOF + RBV for genotype 1 and prior failure to SOF
Wyles D. Hepatology 2015; 61:1793-7

SOF/VEL ± RBV in genotype 3 with compensated cirrhosis
Esteban R. Gastroenterology. 2018; 155:1120-7

SOF/VEL in liver transplantation with genotype 1-4 infection
Agarwal K, J Hepatol 2018; May 29 (ePub ahead of print)

Sofosbuvir/velpatasvir for 12 weeks in liver transplant recipients with genotype 1-4
Agarwal K. J Hepatol. 2018; 69:603-7

SOLAR-1 Study: LDV/SOF + RBV in advanced liver disease
Charlton M. Gastroenterology 2015 ; 149: 649-659

SOLAR-2 Study: LDV/SOF + RBV in decompensated and post-liver transplant with genotype 1 or 4
Manns M. Lancet Infect Dis. 2016 ;16:685-97; Manns M. EASL 2015. Abs. GO2 ; Forns X. EASL 2015;Abs. P0779

STREAGER Study: EBR/GZR for 8 weeks in genotype 1b without severe fibrosis
Abergel A. EASL 2018, Abs. LBP-010

Study 337-1119: LDV/SOF in genotype 5
Abergel A. Lancet Infect Dis. 2016;16:459-64

SURVEYOR-II study – Part 3: glecaprevir/pibrentasvir ± RBV in genotype 3 with treatment experience and/or cirrhosis
Wyles D. Hepatology 2017 ; Sept 19 (ePub)

SURVEYOR-II Study - Part 4: glecaprevir/pibrentasvir for 8 weeks in genotype 2, 4, 5 or 6
Asselah T. Clin Gastroenterol Hepatol 2017 ; Sept 22 (Epub)

SURVEYOR-I et II study – Part 2 in cirrhosis: Glecaprevir + Pibrentasvir in genotypes 1 or 3
Gane E. Gastroenterology 2016;151:651-9

SURVEYOR-I Study - Part 1: glecaprevir + pibrentasvir in genotype 1 – Phase II
Kwo PY. J Hepatol 2017; 67 :263-71

SURVEYOR-I Study - Part 2: glecaprevir + pibrentasvir in genotype 1, 4, 5, 6 – Phase II
Kwo PY. J Hepatol 2017; 67 :263-71

SURVEYOR-II study - Part 1: glecaprevir + pibrentasvir ± RBV in genotypes 2 or 3 – Phase II
Kwo PY. J Hepatol 2017; 67 :263-71

SURVEYOR-II study - Part 2: glecaprevir + pibrentasvir in genotypes 2 or 3 – Phase II
Kwo PY. J Hepatol 2017; 67 :263-71

SWIFT-C study: SOF + RBV or LDV/SOF for acute hepatitis C in HIV-infected patients
Naggie S. Clin Infect Dis 2017; 64:1035-42 ; Naggie S. AASLD 2017, Abs. 196

SYNERGY GT1 Study: LDV/SOF ± (GS-9669 or GS-9451) in genotype 1
Kohli A. Lancet 2015;385:1107-13

SYNERGY-D Study: LDV/SOF retreatment in genotype 1 failing short-course LDV/SOF
Wilson EM. Clin Infect Dis 2016; 62:230-8

TOPAZ-II Study: OBV/PTV/r + DSV ± RBV for genotype 1
Neau R. AASLD 2015, Abs. 1065

TRILOGY-3 Study: SOF/VEL/VOX ± RBV in DAA-experienced patients - Phase II
Lawitz E. Hepatology 2017; 65:1803-9

TURQUOISE-I Study: ombitasvir/paritaprevir/ritonavir + dasabuvir + ribavirin for HCV in HIV co-infected patients
Sulkowski MS, JAMA 2015;315:1223-31 ; Wyles D. J Infect Di 2017; 215:599-605

TURQUOISE-II Study: ombitasvir/paritaprevir/ritonavir + dasabuvir + ribavirin for HCV with cirrhosis
Poordad F, NEJM 2014;370:1973-82

TURQUOISE-III Study: ombitasvir/paritaprevir/ritonavir + dasabuvir for genotype 1b with cirrhosis
Feld JJ. J Hepatol 2016; 64:301-7

UNITY-1 Study: daclatasvir/asunaprevir/beclabuvir in genotype 1 without cirrhosis
Poordad F. JAMA 2015;313:1728-35

UNITY-2 Study: daclatasvir/asunaprevir/beclabuvir + RBV in genotype 1 with compensated cirrhosis
Muir AJ. JAMA 2015;313:1736-44

VALENCE Study: SOF + RBV for HCV genotypes 2 and 3
Zeuzem S. NEJM 2014;370:1993-2001